Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program

Tue Mar 5, 2013 4:30pm EST

* Reuters is not responsible for the content in this press release.

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130305:nGNXUXHOGa

CAMBRIDGE, Mass., March 5, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc.
http://www.globenewswire.com/newsroom/ctr?d=10024125&l=1&a=Aegerion%20Pharmaceuticals%2C%20Inc.&u=http%3A%2F%2Fwww.aegerion.com%2F
 (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of
innovative, life-altering therapies for patients with debilitating and often fatal rare diseases,
today announced that on March 1, 2013, Aegerion granted stock options to purchase an aggregate of
35,500 shares of common stock to four new employees under the inducement stock option program
described below. Each stock option has an exercise price per share equal to $31.31, the closing
price of Aegerion's common stock on the grant date; vests in equal monthly installments over four
years; has a ten year term; and is subject to the terms and conditions of Aegerion's Inducement
Award Stock Option Plan, and the terms and conditions of a stock option agreement covering the
grant.

As Aegerion previously announced, in support of the company's build of its U.S. commercial
organization and international expansion, the Compensation Committee of the Company's Board of
Directors approved the reservation of 1,000,000 shares of common stock to be used exclusively for
the grant of non-qualified stock options to individuals who were not previously an employee or
non-employee director of Aegerion (or following a bona fide period of non-employment), as an
inducement new hire stock option award material to an individual's entry into employment within
the meaning of Rule 5635(c)(4) of the NASDAQ Listing Rules (Inducement Stock Options).

About Aegerion Pharmaceuticals
http://www.globenewswire.com/newsroom/ctr?d=10024125&l=3&a=Aegerion%20Pharmaceuticals&u=http%3A%2F%2Fwww.aegerion.com%2F


Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and
commercialization of innovative, life-altering therapies for patients with debilitating, often
fatal, rare diseases. For more information about the company, please visit www.aegerion.com
http://www.globenewswire.com/newsroom/ctr?d=10024125&l=4&a=www.aegerion.com&u=http%3A%2F%2Fwww.aegerion.com%2F
.

The Aegerion Pharmaceuticals, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=16441
http://www.globenewswire.com/newsroom/ctr?d=10024125&l=5&u=http%3A%2F%2Fwww.globenewswire.com%2Fnewsroom%2Fprs%2F%3Fpkgid%3D16441

CONTACT: Aegerion Pharmaceuticals, Inc.
         Amanda Murphy
         Manager, Investor Relations
         (857) 242-5024